Effect of Socheongryong-tang and Yeongyopaedok-san in Upper Respiratory Tract Infection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

480 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-09-30

Study Completion Date

2009-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether Socheongryong-tang (SCRT) and Yeongyopaedok-san (YPS) are effective in the treatment of upper respiratory tract infection.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Recovery of Respiratory System in COVID-19 Patients

NCT04954222

Covid19

COMPLETED

To Evaluate Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia

NCT04500132

COVID-19

COMPLETED PHASE2

A Pilot Study for the Collection Of Vocalized, Individual Digital Cough Sound Recordings to Screen for COVID-19

NCT04864535

Covid19

UNKNOWN

Point of Care Polymerase Chain Reaction (PCR) Diagnostics of Respiratory Tract Infections in General Practice

NCT06120153

Respiratory Tract Infections

ACTIVE_NOT_RECRUITING NA

Using Social Influencers for Public Health Education on Antibiotic Use and Antimicrobial Resistance

NCT06998576

Community Members

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Upper respiratory tract infections (URTIs) are the most prevalent disease of human beings, it incur a significant health burden on populations in terms of human suffering and economic losses. Usually, antibiotic therapy is not helpful since most infections are virally induced. Over 200 serologically different viral types are responsible for human URTIs, so that preventions of URTIs including vaccination are impassable. SCRT and YPS are widely used to treat the respiratory disease. The objective of this study is to determine the efficacy of SCRT and YPS in symptomatic relief of patients with URTIs.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Upper Respiratory Tract Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Placebo (encapsulated starch + lactose)

Group Type EXPERIMENTAL

Placebo

Intervention Type DRUG

4 capsules, three times daily, for 7days or within symptom disappearance

SCRT(Socheongryong-tang )

encapsulated Socheongryong-tang extract

Group Type EXPERIMENTAL

SCRT

Intervention Type DRUG

4 capsules,three times daily, for 7days or within symptom disappearance

YPS (Yeongyopaedok-san)

Encapsulated Yeongyopaedok-san extract

Group Type EXPERIMENTAL

YPS

Intervention Type DRUG

4 capsules, three times daily, for 7days or within symptom disappearance

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SCRT

4 capsules,three times daily, for 7days or within symptom disappearance

Intervention Type DRUG

YPS

4 capsules, three times daily, for 7days or within symptom disappearance

Intervention Type DRUG

Placebo

4 capsules, three times daily, for 7days or within symptom disappearance

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Xiao-qing-long-tang Lian-qiao-bai-du-san

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18\~60 years old
* Clinical diagnosis of common cold
* Occurring no longer than 48 hours before enrollment
* Presented with runny nose, sore throat, plugged nose, scratchy throat, cough, hoarseness, headache, muscle ache (runny nose, sore throat and at least 1 of others or 1 of runny nose, sore throat and at least 3 of others)

Exclusion Criteria

* Allergic rhinitis, asthma, COPD, sinusitis (2 and more recurrence per year), septal deviation, anatomical otitis media, exudative pharyngitis
* Received antihistamines, NSAIDs, corticosteroids, antibiotics, decongestants
* Hepatic cancer, liver cirrhosis, renal failure, congestive heart failure
* Pregnant or lactation

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No